Lumacaftor
Back to searchMolecule Structure
Scientific Name
Lumacaftor
Description of the Drug
Lumacaftor is a protein chaperone used in combination with ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the F508del mutation in the CFTR gene.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09280
http://www.drugbank.ca/drugs/DB09280
Brand Name(s)
Not Available
Company Owner(s)
Vertex Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Cystic fibrosis transmembrane conductance regulator | SINGLE PROTEIN | STABILISER | CHEMBL4051 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL377028 |
| PharmGKB | PA166114483 |
| Human Metabolome Database | HMDB0247669 |
| DrugBank | DB09280 |
| PubChem: Thomson Pharma | 26654506 |
| PubChem | 16678941 |
| LINCS | LSM-45571 |
| Nikkaji | J3.299.847J |
| PDBe | VX8 |
| BindingDB | 50289703 |
| EPA CompTox Dashboard | DTXSID30239523 |
| DrugCentral | 5010 |
| ChemicalBook | CB32489655 |
| Guide to Pharmacology | 7481 |
| rxnorm | LUMACAFTOR |
| PubChem: Drugs of the Future | 125299339 |
| ChEBI | 90951 |
| ZINC | ZINC000064033452 |
